Brintellix

Land: Europeiska unionen

Språk: engelska

Källa: EMA (European Medicines Agency)

Köp det nu

Bipacksedel Bipacksedel (PIL)
16-01-2024
Produktens egenskaper Produktens egenskaper (SPC)
16-01-2024

Aktiva substanser:

Vortioxetine

Tillgänglig från:

H. Lundbeck A/S

ATC-kod:

N06AX26

INN (International namn):

vortioxetine

Terapeutisk grupp:

Psychoanaleptics,

Terapiområde:

Depressive Disorder, Major

Terapeutiska indikationer:

Treatment of major depressive episodes in adults.

Produktsammanfattning:

Revision: 23

Bemyndigande status:

Authorised

Tillstånd datum:

2013-12-18

Bipacksedel

                                72
B. PACKAGE LEAFLET
v.
77.0
REG_00028683
73
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
BRINTELLIX 5 MG FILM-COATED TABLETS
vortioxetine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Brintellix is and what it is used for
2.
What you need to know before you take Brintellix
3.
How to take Brintellix
4.
Possible side effects
5.
How to store Brintellix
6.
Contents of the pack and other information
1.
WHAT BRINTELLIX IS AND WHAT IT IS USED FOR
Brintellix contains the active substance vortioxetine. It belongs to a
group of medicines called
antidepressants.
Brintellix is used to treat major depressive episodes in adults.
Brintellix has been shown to reduce the broad range of depressive
symptoms, including sadness, inner
tension (feeling anxious), sleep disturbances (reduced sleep), reduced
appetite, difficulty in
concentrating, feelings of worthlessness, loss of interest in
favourite activities, feeling of being slowed
down.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE BRINTELLIX
DO NOT TAKE BRINTELLIX:
-
if you are allergic to vortioxetine or any of the other ingredients of
this medicine (listed in
section 6).
-
if you are taking other medicines for depression known as
non-selective monoamine oxidase
inhibitors or selective MAO-A inhibitors. Ask your doctor if you are
uncertain.
WARNINGS AND PRECAUTIONS
Talk to your doctor or pharmacist before taking Brintellix if you:
-
are taking medicines with a so-called serotonergic effect, such as:
-
tramadol and similar medicines (strong painkillers).
-
sumatr
                                
                                Läs hela dokumentet
                                
                            

Produktens egenskaper

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
v.
77.0
REG_00028683
2
1.
NAME OF THE MEDICINAL PRODUCT
Brintellix 5 mg film-coated tablets
Brintellix 10 mg film-coated tablets
Brintellix 15 mg film-coated tablets
Brintellix 20 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Brintellix 5 mg film-coated tablets
Each film-coated tablet contains vortioxetine hydrobromide equivalent
to 5 mg vortioxetine.
Brintellix 10 mg film-coated tablets
Each film-coated tablet contains vortioxetine hydrobromide equivalent
to 10 mg vortioxetine.
Brintellix 15 mg film-coated tablets
Each film-coated tablet contains vortioxetine hydrobromide equivalent
to 15 mg vortioxetine.
Brintellix 20 mg film-coated tablets
Each film-coated tablet contains vortioxetine hydrobromide equivalent
to 20 mg vortioxetine.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet)
Brintellix 5 mg film-coated tablets
Pink, almond-shaped (5 x 8.4 mm) film-coated tablet engraved with
“TL” on one side and “5” on the
other side.
Brintellix 10 mg film-coated tablets
Yellow, almond-shaped (5 x 8.4 mm) film-coated tablet engraved with
“TL” on one side and “10” on
the other side.
Brintellix 15 mg film-coated tablets
Orange, almond-shaped (5 x 8.4 mm) film-coated tablet engraved with
“TL” on one side and “15” on
the other side.
Brintellix 20 mg film-coated tablets
Red, almond-shaped (5 x 8.4 mm) film-coated tablet engraved with
“TL” on one side and “20” on the
other side.
v.
77.0
REG_00028683
3
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Brintellix is indicated for the treatment of major depressive episodes
in adults.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The starting and recommended dose of Brintellix is 10 mg vortioxetine
once daily in adults less than
65 years of age.
Depending on individual patient response, the dose may be increased to
a maximum of 20 mg
vortioxetine once daily or decreased to a minimum of 5 mg vortioxetine
once daily.
After the dep
                                
                                Läs hela dokumentet
                                
                            

Dokument på andra språk

Bipacksedel Bipacksedel bulgariska 16-01-2024
Produktens egenskaper Produktens egenskaper bulgariska 16-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport bulgariska 14-01-2014
Bipacksedel Bipacksedel spanska 16-01-2024
Produktens egenskaper Produktens egenskaper spanska 16-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport spanska 14-01-2014
Bipacksedel Bipacksedel tjeckiska 16-01-2024
Produktens egenskaper Produktens egenskaper tjeckiska 16-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport tjeckiska 14-01-2014
Bipacksedel Bipacksedel danska 16-01-2024
Produktens egenskaper Produktens egenskaper danska 16-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport danska 14-01-2014
Bipacksedel Bipacksedel tyska 16-01-2024
Produktens egenskaper Produktens egenskaper tyska 16-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport tyska 14-01-2014
Bipacksedel Bipacksedel estniska 16-01-2024
Produktens egenskaper Produktens egenskaper estniska 16-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport estniska 14-01-2014
Bipacksedel Bipacksedel grekiska 16-01-2024
Produktens egenskaper Produktens egenskaper grekiska 16-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport grekiska 14-01-2014
Bipacksedel Bipacksedel franska 16-01-2024
Produktens egenskaper Produktens egenskaper franska 16-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport franska 14-01-2014
Bipacksedel Bipacksedel italienska 16-01-2024
Produktens egenskaper Produktens egenskaper italienska 16-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport italienska 14-01-2014
Bipacksedel Bipacksedel lettiska 16-01-2024
Produktens egenskaper Produktens egenskaper lettiska 16-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport lettiska 14-01-2014
Bipacksedel Bipacksedel litauiska 16-01-2024
Produktens egenskaper Produktens egenskaper litauiska 16-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport litauiska 14-01-2014
Bipacksedel Bipacksedel ungerska 16-01-2024
Produktens egenskaper Produktens egenskaper ungerska 16-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport ungerska 14-01-2014
Bipacksedel Bipacksedel maltesiska 16-01-2024
Produktens egenskaper Produktens egenskaper maltesiska 16-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport maltesiska 14-01-2014
Bipacksedel Bipacksedel nederländska 16-01-2024
Produktens egenskaper Produktens egenskaper nederländska 16-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport nederländska 14-01-2014
Bipacksedel Bipacksedel polska 16-01-2024
Produktens egenskaper Produktens egenskaper polska 16-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport polska 14-01-2014
Bipacksedel Bipacksedel portugisiska 16-01-2024
Produktens egenskaper Produktens egenskaper portugisiska 16-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport portugisiska 14-01-2014
Bipacksedel Bipacksedel rumänska 16-01-2024
Produktens egenskaper Produktens egenskaper rumänska 16-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport rumänska 14-01-2014
Bipacksedel Bipacksedel slovakiska 16-01-2024
Produktens egenskaper Produktens egenskaper slovakiska 16-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport slovakiska 14-01-2014
Bipacksedel Bipacksedel slovenska 16-01-2024
Produktens egenskaper Produktens egenskaper slovenska 16-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport slovenska 14-01-2014
Bipacksedel Bipacksedel finska 16-01-2024
Produktens egenskaper Produktens egenskaper finska 16-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport finska 14-01-2014
Bipacksedel Bipacksedel svenska 16-01-2024
Produktens egenskaper Produktens egenskaper svenska 16-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport svenska 14-01-2014
Bipacksedel Bipacksedel norska 16-01-2024
Produktens egenskaper Produktens egenskaper norska 16-01-2024
Bipacksedel Bipacksedel isländska 16-01-2024
Produktens egenskaper Produktens egenskaper isländska 16-01-2024
Bipacksedel Bipacksedel kroatiska 16-01-2024
Produktens egenskaper Produktens egenskaper kroatiska 16-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport kroatiska 14-01-2014

Sök varningar relaterade till denna produkt

Visa dokumenthistorik